Immuneering Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
March 24 2022 - 6:55AM
Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
using translational bioinformatics to advance a pipeline of product
candidates designed to benefit large populations of patients with
cancer and other diseases, today announced that management will
present at the 21st Annual Needham Virtual Healthcare Conference to
share commentary around the Company’s pipeline, platform, and
business strategy. Participating will be Ben Zeskind, Ph.D.,
Co-Founder, President and Chief Executive Officer, Biren Amin, MBA,
Chief Financial Officer, Brett Hall, Ph.D., Chief Scientific
Officer, and Scott Barrett, M.D., Chief Medical Officer.
The conference is being held from April 11 – 14, 2022.
Immuneering will present virtually per the following
details:Format: Company presentation and 1x1 Investor
MeetingsPresentation: April 12 from 3:45-4:25 PM ET in Track 2
The presentations will be webcast live and archived for 30 days
in the Investor Relations section of Immuneering’s website at
Events & Presentations | Immuneering Corporation or at
https://wsw.com/webcast/needham117/imrx/2281568.
About Immuneering
Corporation Immuneering
aims to improve patient outcomes by advancing a unique pipeline of
oncology and neuroscience product candidates developed using its
translational bioinformatics platform. Immuneering has more than a
decade of experience applying translational bioinformatics to
generate insights into drug mechanism of action and patient
treatment response. Building on this experience, Immuneering’s
disease-agnostic discovery platform enables the company to create
product candidates based on 1) biological insights that are both
counterintuitive and deeply rooted in data, and 2) novel chemistry.
Immuneering’s lead product candidate IMM-1-104 is designed to be a
highly selective dual-MEK inhibitor that further disrupts KSR to
modulate the signaling dynamics of the MAPK pathway. Specifically,
it is designed to drive deep cyclic inhibition that deprives tumor
cells of the sustained proliferative signaling required for rapid
growth, while providing a cadenced, moderate level of signaling
sufficient to spare healthy cells. IMM-1-104 is being developed to
treat advanced solid tumors in patients harboring RAS mutations,
and is translationally guided by Immuneering’s proprietary,
human-aligned 3D tumor modeling platform combined with
patient-aligned bioinformatics. In addition to
IMM-1-104, Immuneering is evaluating its MEK-io product
candidate, IMM-6-415, in IND-enabling studies, and has five other
oncology programs in the discovery stage that are designed to
target components of the MAPK or mTOR pathway, as well as two
discovery stage neuroscience programs.
Forward-Looking StatementsThis press release
includes certain disclosures that contain "forward-looking
statements," including, without limitation, statements regarding
Immuneering’s expectations regarding the sufficiency of
Immuneering’s cash, cash equivalents and marketable securities, its
full year GAAP operating expenses for 2022, the treatment potential
of IMM-1-104 and IMM-6-415, the timing of submission of the IND and
commencement of clinical trials for IMM-1-104 and IMM-6-415, and
Immuneering’s ability to advance its pipeline and further diversify
its portfolio and make progress towards its longstanding goal of
creating better medicines for cancer patients. Forward-looking
statements are based on Immuneering’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Factors that could cause actual results to
differ include, but are not limited to, the risks inherent in
oncology and neuroscience drug development, including target
discovery, target validation, lead compound identification, lead
compound optimization, preclinical studies and clinical trials.
These and other risks and uncertainties are described more fully in
the section titled "Risk Factors" in Immuneering’s most recent Form
10-K filed with the U.S. Securities and Exchange Commission.
Forward-looking statements contained in this announcement are made
as of this date, and Immuneering undertakes no duty to update such
information except as required under applicable law.
Corporate Contact:Rebecca Kusko,
Ph.D.Immuneering Corporation617-500-8080rkusko@immuneering.com
Investor Contact:Susan A. NoonanS.A. Noonan
Communications917-513-5303susan@sanoonan.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024